• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Serum transgelin is a novel prognostic biomarker for COVID-19 patients

tetano

Editor, Senior Moderator
Front Immunol


. 2024 Nov 29:15:1423182.
doi: 10.3389/fimmu.2024.1423182. eCollection 2024. Serum transgelin is a novel prognostic biomarker for COVID-19 patients

Lei Gao[SUP] 1 2 [/SUP], Ying Liu[SUP] 1 2 [/SUP], Qi-Yuan He[SUP] 1 2 [/SUP], Yu Wang[SUP] 1 2 [/SUP], Ya-Lin Jiang[SUP] 3 [/SUP], Jin Yang[SUP] 1 2 [/SUP], Lin Fu[SUP] 1 2 [/SUP], Hui Zhao[SUP] 1 2 [/SUP]



Affiliations
Abstract

Background: Transgelin is a central actin-binding protein of the calponin family and involved in the process of multiple pulmonary diseases. Nevertheless, the role of transgelin in Coronavirus disease 2019 (COVID-19) patients is confusing.
Methods: All 317 COVID-19 patients were recruited from two hospital. Peripheral blood was collected from the fasting patients at the onset and convalescent phases. Demographic data and clinical information were obtained. The expression of serum transgelin was estimated using ELISA.
Results: The expression of serum transgelin on admission was gradually elevated in parallel with the increased severity scores of COVID-19. After treatment, serum transgelin expression was reduced during the convalescent phase. Spearman correlative analyses found that serum transgelin expression was closely correlated to lots of clinical parameters. Besides, serum transgelin was positively associated with severity scores. Follow-up research found that serum higher transgelin on admission elevated the risks of mechanical ventilation, vasoactive agent utilization, ICU admission, death, and longer hospital stays during hospitalization through a prospective cohort study. Additionally, there were similarly predictive capacities for critical patients and death between serum transgelin on admission and severity scores among COVID-19 patients.
Conclusions: The expression of serum transgelin is positively with the severity and poorly prognostic outcomes among COVID-19 patients, indicating that transgelin is implicated in the pathological process of COVID-19. Transgelin can assist in the risk stratification and revealing the pathological mechanisms of COVID-19.

Keywords: COVID-19; cohort study; prognosis; severity; transgelin.

 
Back
Top Bottom